World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
133
Citations
79958
World Ranking
2197
National Ranking
233

Robert E. Coleman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Robert E. Coleman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 896 publications — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Robert E. Coleman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Robert E. Coleman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 133 D-Index — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Robert E. Coleman is affiliated with the University of Sheffield in the United Kingdom. Their research focuses primarily on medicine, with significant contributions to subfields such as oncology, radiology, nuclear medicine and imaging, cancer research, pulmonary and respiratory medicine, and surgery.

The scientist has published extensively on topics related to bone health and treatments, radiopharmaceutical chemistry and applications, cancer diagnosis and treatment, breast cancer treatment studies, management of metastatic bone disease, bone health and osteoporosis research, and estrogen and related hormone effects.

Frequent publication venues for their work include the Journal of Bone Oncology, The Lancet Oncology, Cancer Research, Annals of Oncology, and JAMA Oncology.

Some of Robert E. Coleman's recent papers include:

  • Bone metastases, 2020, Nature Reviews Disease Primers
  • Bone health in cancer: ESMO Clinical Practice Guidelines, 2020, Annals of Oncology
  • Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials, 2021, The Lancet Oncology
  • Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14,324 women in 16 trials, 2023, The Lancet
  • POSNOC-POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes, 2021, BMJ Open

The scientist frequently collaborates with other researchers including Janet E. Brown, David Dodwell, David Cameron, Judith M. Bliss, and Jack Cuzick.

Best Publications

  • Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

    C. Parker;S. Nilsson;S. Nilsson;D. Heinrich;S. I. Helle

  • Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity

    Robert E. Coleman

  • A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.

    R. C Coombes;E. Hall;L. J. Gibson;R. Paridaens

  • Metastatic bone disease: clinical features, pathophysiology and treatment strategies.

    R.E. Coleman

  • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

    Ian Smith;Marion Procter;Richard D Gelber;Sébastien Guillaume

  • The clinical course of bone metastases from breast cancer.

    RE Coleman;RD Rubens

  • Adjuvant docetaxel for node-positive breast cancer.

    Miguel Martin;Tadeusz Pienkowski;John R Mackey;Marek Pawlicki

  • Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

    Lee S. Rosen;David Gordon;Mary Kaminski;Anthony Howell

  • Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.

    Lee S Rosen;David Gordon;Mary Kaminski;Anthony Howell

  • Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

    RC Coombes;LS Kilburn;CF Snowdon;R Paridaens

  • Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer : results of a phase 3, randomised, placebo-controlled trial.

    Matthew R Smith;Fred Saad;Robert Coleman;Neal Shore

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

    W ten Bokkel Huinink;M Gore;J Carmichael;A Gordon

  • Adjuvant ovarian suppression in premenopausal breast cancer

    Prudence A. Francis;Prudence A. Francis;Meredith M. Regan;Gini F. Fleming;István Láng

  • Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

    J. Bergh;K. Pritchard;K. Albain;S. Anderson

  • Phase III Randomized Trial of Docetaxel–Carboplatin Versus Paclitaxel–Carboplatin as First-line Chemotherapy for Ovarian Carcinoma

    Paul Vasey;Gordon C Jayson;Alan Gordon;Hani Gabra

  • Pathologic fractures correlate with reduced survival in patients with malignant bone disease.

    Fred Saad;Allan Lipton;Richard Cook;Yin Miao Chen

  • A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.

    Jean Jacques Body;Thierry Facon;Robert E. Coleman;Allan Lipton

  • Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study

    James R. Berenson;Lee S. Rosen;Anthony Howell;Lester Porter

  • Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors

    Janet E. Brown;Richard J. Cook;Pierre Major;Pierre Major;Allan Lipton

Frequent Co-Authors

Allan Lipton
Allan Lipton Penn State Milton S. Hershey Medical Center
Richard J. Cook
Richard J. Cook University of Waterloo
Jean-Jacques Body
Jean-Jacques Body Université Libre de Bruxelles
Chris Parker
Chris Parker Institute of Cancer Research
Fred Saad
Fred Saad University of Montreal
Anthony Howell
Anthony Howell University of Manchester
Matthew R. Smith
Matthew R. Smith Harvard University
Judith M. Bliss
Judith M. Bliss Institute of Cancer Research
Walter M Gregory
Walter M Gregory University of Leeds
Martine Piccart
Martine Piccart Université Libre de Bruxelles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in medical careers beyond traditional MD paths, there are many flexible options available online. A popular route is pharmacy, where pharm d online programs let students earn a Doctor of Pharmacy from accredited institutions, preparing for vital roles in patient care and medication management.

For those passionate about healthcare data and technology, an online mhi (Master’s in Health Information) can be an excellent choice, opening doors to health informatics and hospital administration roles.

If you are looking for a quicker entry into the healthcare workforce, exploring medical billing and coding cost will help you understand the affordable online certificate programs that can launch careers in medical administration and insurance processing.

Finally, those seeking advanced clinical responsibilities might consider affordable online fnp programs. These pathways allow registered nurses to become certified Family Nurse Practitioners, often with online coursework and flexible schedules.

Each of these degrees supports growing healthcare fields, offering online convenience and diverse career opportunities within the medical sector.

Best Scientists Citing Robert E. Coleman

Trending Scientists

Recently Published Articles